Featured Research

from universities, journals, and other organizations

Alphavirus-based vaccine may slow some cancers

Date:
August 3, 2010
Source:
Duke University Medical Center
Summary:
An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to new research. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

Scientists removed the genes that enable the Venezuelan equine encephalitis virus -- an alphavirus -- to replicate itself, and replaced them with genes that make the biomarker CEA, present in many malignant colon, breast and lung cells.

"Alphaviruses have been used before in designing treatments for infectious diseases, but we believe this is the first time one has been used in patients with cancer," said Michael Morse, MD, associate professor of medicine at Duke and the lead author of the study appearing online in the Journal of Clinical Investigation.

The Phase I/II study included 28 patients with advanced cases of lung, colon, breast, appendix or pancreatic cancers who had already been treated with multiple courses of chemotherapy, but whose cancers kept coming back.

Cancer vaccines, unlike traditional vaccines, are designed to boost the body's own immune system to recognize and destroy tumors, not prevent disease. Scientists often use genetically altered viruses as vaccines, stripping the virus of any harmful parts and inserting genes related to their anticancer strategy. But in many cases, the immune system still sees the incoming virus as a foreign invader and springs into action, generating antibodies and T cells that destroy it before it has a chance to do any good.

Based on earlier research, investigators at Duke believed that by using the alphavirus for Venezuelan equine encephalitis as a carrier they might be able to thwart that response.

"The beauty of alphaviruses is that they are naturally attracted to dendritic cells, cells that stimulate the production of large numbers of T cells and antibodies," says Morse. "Essentially, we were hoping that once infected, the dendritic cells would activate T cells and antibodies to go after anything that had the tumor antigen CEA on it -- in this case, the quickly growing cancer cells."

Participants received up to four injections plus booster shots of the vaccine over a period of three months. At the end of the study, two patients with no evidence of disease remained in remission; two patients were able to maintain stable disease, and one patient with pancreatic cancer saw a lesion in his liver disappear. The other patients in the trial did not respond to the therapy.

"Remember, these were patients with very advanced disease that nothing else had been able to stop," says Morse, a member of the Duke Comprehensive Cancer Center and a specialist in vaccine design. "We believe that in this small number of patients, the vaccine was able to stimulate the body's defense system to destroy significant numbers of cancer cells despite the presence of an army of neutralizing antibodies and regulatory T cells."

Morse says those who seemed to benefit the most were those who had the smallest amount of tumor. Because of this, he says his team is planning future trials that will test the vaccine in people with cancers that have been removed, but who are high risk of recurrence. Other trials will couple the vaccine with additional immune system stimulants such as interleukin-12 that may make the vaccine more powerful.

Grants from the National Cancer Institute and the Department of Defense supported the work.

Colleagues from Duke who helped with the study include senior author H. Kim Lyerly, director of the Duke Comprehensive Cancer Center; Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Gayathri Devi, Bruce Burnett, and Timothy Clay. Additional co-authors include Peter Berglund and Sarah Negri, from Alphavax, Inc.; and Bolyn Hubby and Jonathan Smith, from Liquidia Technologies, Inc.

Lyerly is a member of the scientific advisory board of Alphavax.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Alphavirus-based vaccine may slow some cancers." ScienceDaily. ScienceDaily, 3 August 2010. <www.sciencedaily.com/releases/2010/08/100802125815.htm>.
Duke University Medical Center. (2010, August 3). Alphavirus-based vaccine may slow some cancers. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2010/08/100802125815.htm
Duke University Medical Center. "Alphavirus-based vaccine may slow some cancers." ScienceDaily. www.sciencedaily.com/releases/2010/08/100802125815.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins